| [1]MORIYAMA T,TANAKA K,IWASAKI C,et al.Prognosis in IgA nephropathy:30-year analysis of 1,012 patients at a single center in Japan[J].PLoS One,2014,9(3):e91756.
[2]GUTIERREZ E,MORENO J A,PRAGA M,et al.Persistent microhaematuria with negative or low proteinuria[J].Nefrologia,2014,34(1):110-114.
[3]CHENG G Y,LIU D W,ZHANG N,et al.Clinical and prognostic implications of serum uric acid levels on lgA nephropathy:a cohort study of 348 cases with a mean 5-year follow-up[J].Clin Nephrol,2013,80(1):40-46.
[4]CUI M J,ZHANG B H,XIAO Q F,et al.The relationship between hyperuricaemia and clinic pathology of IgA nephropathy[J].Zhonghua Nei Ke Za Zhi,2011,50(8):659-663.
[5]KATAOKA H,OHARA M,SHIBUI K,et al.Overweight and obesity accelerate the progression of IgA nephropathy:prognostic utility of a combination of BMI and histopathological parameters[J].Clin Exp Nephrol,2012,16(5):706-712.
[6]SHI Y,CHEN W,JALAL D,et al.Clinical outcome of hyperuricemia in IgA nephropathy:a retrospective cohort study and randomized controlled trial[J].Kidney Blood Press Res,2012,35(3):153-160.
[7]Working Group of the International IgA Nephropathy Network and the Renal Pathology Society,CATTRAN D C,COPPO R,et al.The Oxford classification of IgA nephropathy:rationale,clinicopathological correlations,and classification[J].Kidney Int,2009,76(5):534-545.
[8]YANG Y,WEI R B,WANG Y D,et al.Higher HOMA-IR index and correlated factors of insulin resistance in patients with IgA nephropathy[J].Clin Nephrol,2012,78(5):353-358.
[9]DEFRONZO R A.Insulin resistance,lipotoxicity,type2 diabetes and atherosclerosis:the missing links.The Claude Bernard Lecture 2009[J].Diabetologia,2010,53(7):1270-1287.
[10]宋颖,李启富.不同种族胰岛素抵抗状态比较及相关影响因素[J].中国糖尿病杂志,2013,21(1):91-92.
[11]EIRO M,KATOH T,SAKUMA Y,et al.Insulin resistance highly associates with hypertension in IgA nephropathy[J].Clin Nephrol,2003,2(11):71-78.
[12]ROSS W R,MCGILL J B.Epidemiology of obesity and chronic kidney disease[J].Adv Chronic Kidney Dis,2006,13(4):325-335.
[13]NAKAMURA T,FUJIKURA Y,SUGA N,et al.An IgA nephropathy case with highly reduced urinary protein concomitant with reduced obesity[J].Nihon Jinzo Gakkai Shi,2006,48(7):675-679.
[14]MUNTNER P,CORESH J,SMITH J C,et al.Plasma lipids and risk of developing renal dysfunction:the atherosclerosis risk in communities study[J].Kidney Int,2000,58(1):293-301.
[15]胡芳芳.C-反应蛋白对慢性肾功能衰竭患者预后的影响[J].临床医学,2011,31(4):15-17.
[16]PICKUP J C,MATTON M B,CHUANEY G D,et al.NIDDM as a disease of the innate immune system:association of acute-phase reactants and interleukin-6 eith metabolic syndrome X[J].Diabetologia,1997,40(11):1286-1292.
[17]蒙庆旭,唐毓启.IgA肾病患者脂联素和C反应蛋白与胰岛素抵抗的临床研究[J].中国现代药物应用,2012,6(20):37-38.
[18]SMITH N L,PSATY B M,FURBERG C D,et al.Temporal trends in the use of anticoagulants among older adults with altial fibrillation[J].Arch Intem Med,1999,159(14):1574-1578.
[19]SYRJNEN J,MUSTONEN J,PASTERNACK A.Hypertrigly ceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy[J].Nephrol Dial Transplant,2000,15(1):34-42.
[20]KANG D H,PARK S K,LEE I K,et al.Uric acid-induced C-reactive protein expression:implication on cell proliferation and nitric oxide production of human vascular cells[J].J Am Soc Nephrol,2005,16(12):3553-3562.
[21]CORRY D B,ESLAMI P,YAMAMOTO K,et al.Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin systen[J].J Hypertens,2008,26(2):269-275.
[22]杨悦,魏日胞.胰岛素抵抗在IgA 肾病中作用的研究进展[J].中国中西医结合肾病杂志,2011,12(4):361-362. |